Full Year 2024 ImpediMed Ltd Earnings Call Transcript
Key Points
- Gross margin remained high at 87%, indicating strong profitability.
- Core business revenues increased by 14% compared to FY23, driven primarily by the US market.
- Patient tests were up 18%, reflecting the health of the Lymphedema Prevention Program.
- Cash balance at the end of FY24 was $24.6 million, providing a solid financial cushion.
- New executive team and Board are in place, focusing on sustainable growth and cost management.
- Global revenues were down 9%, primarily due to the cessation of Astra Zeneca clinical trials.
- Total contract value (TCV) and unit sales were down compared to FY23.
- Operating expenses remained similar to FY23, including $2.1 million in severance payments.
- Cash outflow from operating activities was $17.8 million, indicating high cash burn.
- Significant reliance on the US market, which accounts for 90% of core business revenue.
Good morning, everybody, and welcome to the ImpediMed FY24 results presentation. With us this morning, we have Parmjot Bains, the Chief Executive Officer, and McGregor Grant, the Chief Financial Officer, who will take us through the presentation that was lodged with the ASX this morning and just a bit of housekeeping, today's webinar is being recorded, including the Q&A and we intend to launch this on the ImpediMed, which website and after the webinar has been completed.
(Operator Instructions) Handing over to Parmjot for the results presentation.
Good morning. Welcome to our ImpediMed investor call for the fiscal year 2024 ending June 2024, and then ImpediMed, our mission really is to improve patient outcomes by setting the new standard of care and fluid and body composition management.
We achieved this for our bioimpedance spectroscopy technology to assess and monitor the fluid composition and tissue composition and patients. Our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
